Centre Hospitalier Universitaire de Nīmes
chu-nimes.frLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
589
Active
108
Phase 3
10
Total enrollment
1,839,103
Pipeline matrix
Showing 28 of 28 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ambulatory surgery under Lidocaine with epinephrine alone | — | — | — | — | — | 1 | |
| Ambulatory surgery under lidocaine with epinephrine plus bicarbonate | — | — | — | — | — | 1 | |
| Vitamin K antagonist | — | — | — | — | — | 1 | |
| Direct oral anticoagulant | — | — | — | — | — | 1 | |
| Buprenorphine | — | — | — | — | — | 1 | |
| Psilocybin | — | — | — | — | 3 | ||
| Patients receiving neoadjuvant therapy before radical nephrectomy | — | — | — | — | — | 1 | |
| Topical anti-Staphylococcus bacteriophage therapy | — | — | — | — | — | 1 | |
| Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy | — | — | — | — | — | 1 | |
| Continuous veino-veinous dialysis with iron-chelator supplemented dialysate | — | — | — | — | — | 1 | |
| Botulinum Toxin - A injections | — | — | — | — | — | 1 | |
| Blood test | — | — | — | — | 3 | ||
| maintenance therapy with bevacizumab | — | — | — | — | — | 1 | |
| maintenance therapy with niraparib | — | — | — | — | — | 1 | |
| enfortumab vedotin plus pembrolizumab in first line setting for advanced upper tract urothelial carcinoma | — | — | — | — | — | 1 | |
| MultiLocus Sequence Typing | — | — | — | — | — | 1 | |
| Constitution of a biobank | — | — | — | — | — | 1 | |
| Protein pump inhibitor therapy systematically | — | — | — | — | — | 1 | |
| Vascularly biological assessment | — | — | — | — | — | 1 | |
| Analysis of vasomotor endothelial function | — | — | — | — | — | 1 | |
| Analysis of arterial compliance | — | — | — | — | — | 1 | |
| Exploration of microcirculation | — | — | — | — | — | 1 | |
| Venous Doppler Ultrasound | — | — | — | — | — | 1 | |
| Arterial pressure measurement | — | — | — | — | — | 1 | |
| Intima-Media Thickness measurement | — | — | — | — | — | 1 | |
| Exploration of neuropathy | — | — | — | — | — | 1 | |
| Dexmedetomidine | — | — | — | — | — | 1 | |
| Sufentanil | — | — | — | — | — | 1 |
Next readouts
- 2025-01-01
- 2025-02-05
- 2025-05-31
- 2025-09
- 2026-02
- 2026-10
- 2026-11
- 2026-12-01
- 2026-12-15
- 2027-02-01
Top conditions
- Multiple Sclerosis12
- Stroke11
- Low Back Pain10
- Surgery9
- Cancer7
- Stress Disorders, Post-Traumatic7
- Pelvic Organ Prolapse7
- COVID-197
Frequently asked questions about Centre Hospitalier Universitaire de Nīmes
- How many clinical trials does Centre Hospitalier Universitaire de Nīmes have on ClinicalTrials.gov?
- Centre Hospitalier Universitaire de Nīmes is listed as the lead sponsor on 589 clinical trials in ClinicalTrials.gov, 108 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Centre Hospitalier Universitaire de Nīmes's trials are in Phase 3?
- 10 of Centre Hospitalier Universitaire de Nīmes's trials are in Phase 3, spread across 28 active drug programs.
- What therapeutic areas does Centre Hospitalier Universitaire de Nīmes focus on?
- Centre Hospitalier Universitaire de Nīmes's most-studied conditions on ClinicalTrials.gov are Multiple Sclerosis, Stroke, Low Back Pain, Surgery, Cancer.
- When are Centre Hospitalier Universitaire de Nīmes's next clinical trial readouts?
- Centre Hospitalier Universitaire de Nīmes has 10 upcoming primary-completion readouts tracked here; the soonest is “Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract”, expected around 2025-01-01.